NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

HeartSciences Inc. (HSCS) Stock Analysis

HeartSciences Inc. (HSCS) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

HSCS

$3.73

+$0.37 (+11.01%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HSCS with… →

HSCS Key Statistics

As of Sep 4, 2026
Trading
Open
$3.34
Previous Close
$3.36
Day's Range
3.21–3.83
52-Week Range
1.63–3.83
Volume
179.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.86
Valuation
Market Cap
$16.81M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3891.50
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.48
Financials (FY)
Revenue (FY)
$4.32K−0.71%
Net Income (FY)
−$9.14M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.51M
1-Year Return
+12.01%
Dividend and dates
Avg Volume
2.34M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

HSCS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+20.71%
2025−19.11%
2024−77.66%
2023−79.64%
2022 (partial year)−65.29%

As of September 4, 2026.

HSCS Revenue and Earnings by Fiscal Year

FY ends April
Fiscal yearRevenueNet incomeNet margin
2025$4.32K−$9.14M−211666.5%
2024$4.35K−$8.77M−201499.5%
2023$18.60K−$6.61M−35511.9%
2022$5.15K−$6.35M−123384.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.32K$2.55K−$8.41M−$9.14M−211666.5%
2024$4.35K$2.47K−$8.35M−$8.77M−201499.5%
2023$18.60K$12.52K−$6.31M−$6.61M−35511.9%
2022$5.15K$2.35K−$6.11M−$6.35M−123384.3%

Annual figures as reported, in the company's reporting currency. As of April 30, 2026.

HSCS Valuation vs Medical Devices Median

Median of 151 stocks
MetricHSCSMedical Devices medianvs median
Profit margin0.00%−1.69%1.7 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

HeartSciences Inc. (HSCS) carries a market capitalisation of $16.81M. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 14.

The 52-week range on file runs from $1.63 to $3.83. HSCS last closed at $3.73 on September 4, 2026. That is +$0.37 (+11.01%) against the previous close. The latest close sits 128.83% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $4.32K. Against the prior fiscal year total of $4.35K, that is a change of −0.71%. The same year closed with a net loss of $9.14M. The reported profit margin is 0%. That is 1.7 percentage points above the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −3.48.

Across the 4 fiscal years on file, revenue moves from $5.15K in 2022 to $4.32K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 3,891.5 times revenue. On price-to-sales that is 1,307.6 times the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.86. Annualized volatility over the trailing 4 years is 159.68%. Over the trailing twelve months the price has returned +12.01%. Measured over 3 years, that is −62.37% a year compounded.

Growth & Income

The record shows no dividend for HSCS.

So far in 2026 the price is +20.71%. Across the complete calendar years on file, 2025 returned −19.11% and 2023 returned −79.64%. Of the 3 complete calendar years on file, 0 finished higher.

Peer Comparison

HeartSciences Inc. (HSCS) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
HeartSciences Inc. HSCS $16.81M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. HeartSciences Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About HeartSciences Inc.

HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.

Visit website →